Neutralization of BCL-2/X(L) enhances the cytotoxicity of T-DM1 in vivo

One of the most recent advances in the treatment of HER2+ breast cancer is the development of the antibody-drug conjugate, T-DM1. T-DM1 has proven clinical benefits for patients with advanced and/or metastatic breast cancer who have progressed on prior HER2-targeted therapies. However, T-DM1 resista...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Cancer Ther
Glavni autori: Zoeller, Jason J., Vagodny, Aleksandr, Taneja, Krishan, Tan, Benjamin Y., O’Brien, Neil, Slamon, Dennis J., Sampath, Deepak, Leverson, Joel D., Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6758547/
https://ncbi.nlm.nih.gov/pubmed/30962322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0743
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items